Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
MetadataShow full item record
CitationKatz, Tamar, Irit Avivi, Noam Benyamini, Jacalyn Rosenblatt, and David Avigan. 2014. “Dendritic Cell Cancer Vaccines: From the Bench to the Bedside.” Rambam Maimonides Medical Journal 5 (4): e0024. doi:10.5041/RMMJ.10158. http://dx.doi.org/10.5041/RMMJ.10158.
AbstractThe recognition that the development of cancer is associated with acquired immunodeficiency, mostly against cancer cells themselves, and understanding pathways inducing this immunosuppression, has led to a tremendous development of new immunological approaches, both vaccines and drugs, which overcome this inhibition. Both “passive” (e.g. strategies relying on the administration of specific T cells) and “active” vaccines (e.g. peptide-directed or whole-cell vaccines) have become attractive immunological approaches, inducing cell death by targeting tumor-associated antigens. Whereas peptide-targeted vaccines are usually directed against a single antigen, whole-cell vaccines (e.g. dendritic cell vaccines) are aimed to induce robust responsiveness by targeting several tumor-related antigens simultaneously. The combination of vaccines with new immuno-stimulating agents which target “immunosuppressive checkpoints” (anti-CTLA-4, PD-1, etc.) is likely to improve and maintain immune response induced by vaccination.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13454719
- HMS Scholarly Articles